Skip to main content
. 2011 Aug 31;2(11):861–865. doi: 10.1021/ml200176m

Figure 4.

Figure 4

In vivo activity of apratoxin S4 (1e) using a HCT116 xenograft mouse model. (a) Efficacy studies (daily ip). Subcutaneous tumor-bearing mice were injected with 1e (n = 8) or DMSO vehicle (n = 10), and tumor volumes were monitored over time. Error bars indicate SEM. (b) At the end of the efficacy studies, tumors were analyzed by immunoblot analysis for receptor levels. (c) Levels of VEGFR2 were analogously measured in liver tissue of vehicle- vs 1e-treated mice.